Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street

Quest Diagnostics Incorporated stocks have been trading up by 7.52 percent after strong earnings and raised full-year guidance.

Live Update At 14:02:52 EDT: On Thursday, July 23, 2026 Quest Diagnostics Incorporated stock [NYSE: DGX] is trending up by 7.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

DGX has been grinding higher on solid fundamentals and fresh oncology catalysts. Over the recent stretch, Quest Diagnostics stock climbed from the low $210s to a close near $225.50 on 2026/07/23, after tagging an intraday high of $237.78. That’s a meaningful breakout versus the prior range around $205–$215, telling traders that buyers are getting more aggressive on DGX.

Intraday action shows DGX shaking out early weakness, then basing and holding above $220 for most of the afternoon — the kind of steady bid that momentum traders like to see. Fundamentally, Quest Diagnostics generated about $11.04B in revenue over the last year, with an EBIT margin of 14.6% and gross margin over 33%. Those are healthy numbers for a large diagnostics name.

More Breaking News

• EHGO Stock Rockets As Volatility Draws Momentum Traders
• MBLY Stock Slides As Traders Focus On Deep Losses And Support Levels
• Thermo Fisher Scientific Stock Climbs As Analysts Ramp Up Bullish Calls
• OII Stock Jumps As Oceaneering Crushes Q2 Earnings And Lifts Outlook

DGX carries a P/E near 21.5 and price-to-sales around 1.9, signaling the market is willing to pay a quality premium but not an extreme growth multiple. Return on equity north of 14% and solid cash generation — about $278M in operating cash flow last quarter with $164M in free cash flow — back up that quality story. Debt is manageable with interest coverage near 8.8x and a current ratio around 1.2, so liquidity risk is not the main trading worry here.

Why Traders Are Watching DGX’s Oncology Push

Quest Diagnostics has turned its Haystack MRD ctDNA liquid biopsy franchise into the clear headline driver. The New York State Department of Health CLEP approval for the Haystack MRD test is bigger than just another regulatory checkbox. New York is one of the toughest lab markets in the country; when it signs off, it effectively greenlights DGX to run this test nationwide with added credibility. That is exactly what happened: authorization now spans all 50 states.

Traders saw the impact fast. On the day DGX announced that approval, the stock traded near $203.85, up about 3.38%. That kind of single-day move in a large-cap diagnostics name signals real money stepping in, not just retail chatter. The message from the tape: the market believes Haystack MRD can be a meaningful growth leg for Quest Diagnostics.

At the same time, DGX is not just winning on regulation; it’s embedding itself into the oncology workflow. By integrating Haystack MRD and broader genomic profiling into Flatiron Health’s OncoEMR, Quest Diagnostics is putting its tests directly in front of oncologists where they live — inside the chart. The pilot, running with American Oncology Network and other community groups, is just the start. A nationwide rollout in the back half of the year could give roughly 4,700 clinicians at 1,600 cancer sites streamlined access to DGX oncology testing.

For traders, that translates to a simple thesis: more frictionless ordering, more test volume, and stickier relationships in community oncology. In a world where diagnostics is commoditized on price, DGX is competing on integration and clinical relevance. That’s the kind of story that can sustain a trend, not just a one-day pop.

Layer on the Street’s view. Baird raised its DGX target to $236 with a Neutral stance — a nod that valuation has tightened but the numbers still justify a higher bar. Leerink Partners went further, bumping its target to $244 and reiterating an Outperform, while consensus sits overweight with an average target near $226 versus a price still around $205–$225 in recent trading. Translation for active traders: there is a defined “valuation gap” that many funds are watching, even after the recent run.

Conclusion

DGX now has three strong pillars behind the latest price action: regulatory momentum, workflow integration, and supportive analyst targets. The Haystack MRD ctDNA approval from New York, extending access to every U.S. state, signals that Quest Diagnostics is serious about being a long-term player in minimal residual disease testing for solid tumors. That is a fast-growing niche, and traders know leadership spots in new diagnostics categories can be very profitable.

The Flatiron Health OncoEMR integration adds real-world muscle to the story. When 4,700 clinicians at 1,600 locations can order Quest Diagnostics oncology tests with a couple of clicks inside their EHR, DGX is no longer just another lab; it becomes part of the digital backbone of cancer care. That is the kind of structural edge that does not show up in a single-quarter EPS beat but can shape the revenue curve for years.

Technically, DGX has broken above its recent range and is holding higher lows intraday, a pattern momentum-focused traders in the Tim Sykes community watch closely. The stock is not cheap on old-school metrics, but the combination of mid-teens margins, strong cash flow, and new oncology catalysts gives the bulls ammo. As Tim Sykes likes to say, “Smart traders don’t chase hype — they stalk catalysts, study the chart, and move fast when the risk/reward finally lines up.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” For now, DGX is earning a spot on that watchlist — not as a lottery ticket, but as a real business stacking meaningful catalysts.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.